메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색
질문

논문 기본 정보

자료유형
학술저널
저자정보
양혜원 (가천대학교) 안성수 (가천대학교)
저널정보
한국생물공학회 KSBB Journal KSBB Journal Vol.39 No.4(Wn.191)
발행연도
2024.12
수록면
111 - 118 (8page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색
질문

초록· 키워드

오류제보하기
Currently, with the advent of protein and cell therapy, new drug drugs are largely divided into synthetic drugs and biopharmaceuticals, and biopharmaceuticals are composed of proteins, cells, or nucleic acids, and are sensitive to minute changes such as temperature, moisture, and vibration in the production and distribution process, so it is important to maintain safety and effectiveness. Biopharmaceuticals have a long period of preclinical, clinical, and approval from the patent application, so the period is short. When the patent expires, a 'biosimilar' manufactured with similar ingredients is released in the market with high competitiveness. This review examines new drugs with trastuzumab (Herceptin) IgG1 anti-bodies and their biosimilars that have been approved by the FDA, and reports a comparative analysis of the efficacy and safety of these drugs. Herceptin targets the HER2 receptor, which is overexpressed in breast cancer, by Genetech Pharmaceutical Company in the United States, and is an antibody drug used to treat breast and stomach cancer, and it was first approved by the FDA as an original product. Herceptin's five biosimilars are Kanjinti, Ogivri, Herzuma, Ontruzant, and Trazima, and each other pharmaceutical company has been recognized for having similar efficacy and safety to the existing Herceptin. Herceptin and biosimilars can differ in price, manufacturing process, development and approval process. Herceptin and its biosimilars show similar therapeutic effects and safety, which contributes to the commercialization and increased accessibility of biopharmaceuticals. It also increases accessibility at low prices, similar efficacy and safety, and in areas with low supply. For these reasons, it is widely sold worldwide. Although a separate immunoassay is not required in general, it may be necessary to evaluate the immune status according to the underlying disease, immunosuppression status, and previous drug use history of a particular patient. It is important to consult a doctor according to the patient's individual situation to determine the necessary test. Future research on biosimilars needs to focus on evaluating the long-term safety and efficacy of these products.

목차

Abstract
1. INTRODUCTION
2. Mechanism
3. 바이오시밀러 제조방법
4. 허셉틴과 바이오시밀러
5. 주의사항 및 부작용
6. 약물복용
7. Elimination
8. 바이오시밀러의 향후 전망
REFERENCES

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문과 함께 이용한 논문

최근 본 자료

전체보기

댓글(0)

0

UCI(KEPA) : I410-151-25-02-092275609